Search

Your search keyword '"Dizdarevic S"' showing total 127 results
Start Over Author "Dizdarevic S"
127 results on '"Dizdarevic S"'

1. A MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Author

Warren, H., primary, Wagner, T., additional, El-Sheikh, S., additional, Barod, R., additional, Patki, P., additional, Mumtaz, F., additional, Bex, A., additional, Campain, N., additional, Rogers, P., additional, O’Brien, T., additional, Hassan, F., additional, Stewart, G., additional, Mendichovszky, I., additional, Dizdarevic, S., additional, Alanbuki, A., additional, Wah, T., additional, Scarsbrook, A., additional, Wildgoose, W., additional, Vindrola-Padros, C., additional, Pizzo, E., additional, Dehbi, H.M., additional, Gurusamy, K., additional, Emberton, M., additional, and Tran, M.G.B., additional

Published
2023
Full Text
View/download PDF

2. 1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study

Author

O'Sullivan, J., primary, Heinrich, D., additional, Castro Marcos, E., additional, George, S., additional, Song, D.Y., additional, Dizdarevic, S., additional, Baldari, S., additional, Essler, M., additional, de Jong, I.J., additional, Lastoria, S., additional, Hammerer, P.G., additional, Tombal, B., additional, James, N.D., additional, Verholen, F., additional, Meltzer, J., additional, Sandström, P., additional, and Sartor, O., additional

Published
2022
Full Text
View/download PDF

3. 593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

Author

Higano, C.S., primary, Dizdarevic, S., additional, Sundar, S., additional, Agarwal, N., additional, Essler, M., additional, Song, D., additional, George, S., additional, Shore, N.D., additional, Kurtinecz, M., additional, Verholen, F., additional, Sandström, P., additional, Sartor, O., additional, and George, D.J., additional

Published
2021
Full Text
View/download PDF

4. O04 - A MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

Author

Warren, H., Wagner, T., El-Sheikh, S., Barod, R., Patki, P., Mumtaz, F., Bex, A., Campain, N., Rogers, P., O’Brien, T., Hassan, F., Stewart, G., Mendichovszky, I., Dizdarevic, S., Alanbuki, A., Wah, T., Scarsbrook, A., Wildgoose, W., Vindrola-Padros, C., Pizzo, E., Dehbi, H.M., Gurusamy, K., Emberton, M., and Tran, M.G.B.

Published
2023
Full Text
View/download PDF

5. Comparative accuracy and cost-effectiveness of dynamic contrast-enhanced CT and positron emission tomography in the characterisation of solitary pulmonary nodules

Author

Gilbert, Fiona J., Harris, Scott, Miles, K.A., Weir-McCall, Jonathan, Qureshi, N.R., Rintoul, R.C., Dizdarevic, S., Pike, L, Sinclair, Donald, Shah, Andrew, Eaton, Rosemary, Jones, Jeremy, Clegg, A.J., Vitiello, Benedetto, Hill, James, Cook, Andrew, Tzelis, D, Vale, Luke, Brindle, Lucy, Madden, J., Cozens, Kelly, Little, LA, Eichhorst, Kathrin, Moate, P., McClement, C., Peebles, Charles, Bannerjee, A, Han, S., Poon, F.W., Groves, A.M., Kurban, L., Roderick, Paul, Frew, Anthony, Callister, Matthew, Crosbie, P., Gleeson, F.V., Karunasaagarar, K, Kankam, O., George, Steve, Gilbert, Fiona J [0000-0002-0124-9962], Weir-McCall, Jonathan R [0000-0001-5842-842X], Rintoul, Robert Campbell [0000-0003-3875-3780], Crosbie, Phil A [0000-0001-8941-4813], and Apollo - University of Cambridge Repository

Subjects
Male, Pulmonary and Respiratory Medicine, Lung Neoplasms, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Cost-Benefit Analysis, Solitary Pulmonary Nodule, imaging/CT MRI etc, A300, Sensitivity and Specificity, lung cancer, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Humans, Female, Prospective Studies, Radiopharmaceuticals, Tomography, X-Ray Computed
Abstract

Introduction Dynamic contrast-enhanced CT (DCE-CT) and positron emission tomography/CT (PET/CT) have a high reported accuracy for the diagnosis of malignancy in solitary pulmonary nodules (SPNs). The aim of this study was to compare the accuracy and cost-effectiveness of these. Methods In this prospective multicentre trial, 380 participants with an SPN (8–30 mm) and no recent history of malignancy underwent DCE-CT and PET/CT. All patients underwent either biopsy with histological diagnosis or completed CT follow-up. Primary outcome measures were sensitivity, specificity and overall diagnostic accuracy for PET/CT and DCE-CT. Costs and cost-effectiveness were estimated from a healthcare provider perspective using a decision-model. Results 312 participants (47% female, 68.1±9.0 years) completed the study, with 61% rate of malignancy at 2 years. The sensitivity, specificity, positive predictive value and negative predictive values for DCE-CT were 95.3% (95% CI 91.3 to 97.5), 29.8% (95% CI 22.3 to 38.4), 68.2% (95% CI 62.4% to 73.5%) and 80.0% (95% CI 66.2 to 89.1), respectively, and for PET/CT were 79.1% (95% CI 72.7 to 84.2), 81.8% (95% CI 74.0 to 87.7), 87.3% (95% CI 81.5 to 91.5) and 71.2% (95% CI 63.2 to 78.1). The area under the receiver operator characteristic curve (AUROC) for DCE-CT and PET/CT was 0.62 (95% CI 0.58 to 0.67) and 0.80 (95% CI 0.76 to 0.85), respectively (p Conclusions PET/CT has a superior diagnostic accuracy to DCE-CT for the diagnosis of SPNs. Combining both techniques improves the diagnostic accuracy over either test alone and could be cost-effective.

Published
2021
Full Text
View/download PDF

6. Comparative Accuracy and Cost-Effectiveness of Dynamic Contrast Enhanced Computed Tomography and Positron Emission Tomography in the Characterisation of Solitary Pulmonary Nodules

Author

Gilbert, F J, Harris, S, Miles, K A, Weir McCall, J R, Quereshi, N R, Rintoul, R C, Dizdarevic, S, Pike, L, Sinclair, D, Shah, A, Eaton, R, Jones, J, Clegg, Andrew, Benedetto, Valerio, Hill, James Edward, Cook, A, Tzelis, D, Vale, L, Brindle, L, Madden, J, Cozens, K, Little, L A, Eichhorst, K, Moate, P, McClement, C, Peebles, C, Banerjee, A, Han, S, Poon, F W, Groves, A M, Kurban, L, Frew, A J, Callister, M E, Crosbie, P, Gleeson, F V, Karunasaagarar, K, Kankam, O, George, S, Gilbert, F J, Harris, S, Miles, K A, Weir McCall, J R, Quereshi, N R, Rintoul, R C, Dizdarevic, S, Pike, L, Sinclair, D, Shah, A, Eaton, R, Jones, J, Clegg, Andrew, Benedetto, Valerio, Hill, James Edward, Cook, A, Tzelis, D, Vale, L, Brindle, L, Madden, J, Cozens, K, Little, L A, Eichhorst, K, Moate, P, McClement, C, Peebles, C, Banerjee, A, Han, S, Poon, F W, Groves, A M, Kurban, L, Frew, A J, Callister, M E, Crosbie, P, Gleeson, F V, Karunasaagarar, K, Kankam, O, and George, S

Abstract

Introduction: Dynamic contrast-enhanced computed tomography (DCE-CT) and Positron Emission Tomography/Computed Tomography (PET/CT) have a high reported accuracy for the diagnosis of malignancy in solitary pulmonary nodules. The aim of this study was to compare the accuracy and cost-effectiveness of these. Methods: In this prospective multicentre trial, 380 participants with a solitary pulmonary nodule (8-30mm) and no recent history of malignancy underwent DCE-CT and PET/CT. All patients underwent either biopsy with histological diagnosis or completed CT follow-up. Primary outcome measures were sensitivity, specificity, and overall diagnostic accuracy for PET/CT and DCE-CT. Costs and cost-effectiveness were estimated from a healthcare provider perspective using a decision-model. Results: 312 participants (47% female, 68.1±9.0 years) completed the study, with 61% rate of malignancy at 2 years. The sensitivity, specificity, positive predictive value and negative predictive values for DCE-CT were 95.3% [95% CI 91.3;97.5], 29.8% [95% CI 22.3;38.4], 68.2% [95% CI 62.4%;73.5%] and 80.0% [95% CI 66.2;89.1] respectively, and for PET/CT were 79.1% [95% CI 72.7;84.2], 81.8% [95% CI 74.0;87.7], 87.3%[95% CI 81.5;91.5) and 71·2% [95% CI 63.2;78.1]. The area under the receiver operator characteristic curve (AUROC) for DCE-CT and PET/CT was 0.62 [95%CI 0.58;0.67] and 0.80 [95%CI 0.76;0.85] respectively (p<0.001). Combined results significantly increased diagnostic accuracy over PET/CT alone (AUROC=0.90 [95%CI 0.86;0.93], p<0.001). DCE-CT was preferred when the willingness to pay per incremental cost per correctly treated malignancy was below £9000. Above £15500 a combined approach was preferred. Conclusions: PET/CT has a superior diagnostic accuracy to DCE-CT for the diagnosis of solitary pulmonary nodules. Combining both techniques improves the diagnostic accuracy over either test alone and could be cost-effective. (Clinical trials.gov - NCT02013063).

Published
2021

11. Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial.

Author

Weir-McCall, J. R., Harris, S., Miles, K. A., Qureshi, N. R., Rintoul, R. C., Dizdarevic, S., Pike, L., Cheow, Heok K., Gilbert, Fiona J., on behalf of the SPUtNIk investigators, Banerjee, Anindo, Brindle, Lucy, Callister, Matthew, Clegg, Andrew, Cook, Andrew, Cozens, Kelly, Crosbie, Philip, Dizdarevic, Sabina, Eaton, Rosemary, and Eichhorst, Kathrin

Subjects
SOLITARY pulmonary nodule, POSITRON emission tomography computed tomography, LUNG cancer
Abstract

Purpose: To compare qualitative and semi-quantitative PET/CT criteria, and the impact of nodule size on the diagnosis of solitary pulmonary nodules in a prospective multicentre trial. Methods: Patients with an SPN on CT ≥ 8 and ≤ 30 mm were recruited to the SPUTNIK trial at 16 sites accredited by the UK PET Core Lab. Qualitative assessment used a five-point ordinal PET-grade compared to the mediastinal blood pool, and a combined PET/CT grade using the CT features. Semi-quantitative measures included SUVmax of the nodule, and as an uptake ratio to the mediastinal blood pool (SURBLOOD) or liver (SURLIVER). The endpoints were diagnosis of lung cancer via biopsy/histology or completion of 2-year follow-up. Impact of nodule size was analysed by comparison between nodule size tertiles. Results: Three hundred fifty-five participants completed PET/CT and 2-year follow-up, with 59% (209/355) malignant nodules. The AUCs of the three techniques were SUVmax 0.87 (95% CI 0.83;0.91); SURBLOOD 0.87 (95% CI 0.83; 0.91, p = 0.30 versus SUVmax); and SURLIVER 0.87 (95% CI 0.83; 0.91, p = 0.09 vs. SUVmax). The AUCs for all techniques remained stable across size tertiles (p > 0.1 for difference), although the optimal diagnostic threshold varied by size. For nodules < 12 mm, an SUVmax of 1.75 or visual uptake equal to the mediastinum yielded the highest accuracy. For nodules > 16 mm, an SUVmax ≥ 3.6 or visual PET uptake greater than the mediastinum was the most accurate. Conclusion: In this multicentre trial, SUVmax was the most accurate technique for the diagnosis of solitary pulmonary nodules. Diagnostic thresholds should be altered according to nodule size. Trial registration: ISRCTN - ISRCTN30784948. ClinicalTrials.gov - NCT02013063 [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

12. Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

Author

Sternberg, C.N., primary, Tombal, B., additional, Miller, K., additional, Saad, F., additional, Sartor, O., additional, Sade, J.P., additional, Logothetis, C., additional, Bellmunt, J., additional, Dizdarevic, S., additional, Harshman, L.C., additional, Logue, J., additional, Baldari, S., additional, Richardson, T., additional, Bottomley, D., additional, Schostak, M., additional, Bayh, I., additional, Kalinovsky, J., additional, and Higano, C., additional

Published
2018
Full Text
View/download PDF

14. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma.

Author

Dizdarevic, S, Tulchinsky, M, McCready, V, Mihailovic, J, Vinjamuri, S, Buscombe, J, Lee, S, Frangos, S, Sathekge, M, Siraj, Q, Choudhury, P, Bom, H, Franceschi, M, Ugrinska, A, Paez, D, Hussain, R, Mailman, J, Luster, M, Virgolini, I, and On behalf of the WARMTH Thyroid Group

Subjects
*THYROID cancer, *MOLECULAR association
Published
2019
Full Text
View/download PDF

15. Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules—the SPUtNIk study

Author

Qureshi, N R, primary, Rintoul, R C, additional, Miles, K A, additional, George, S, additional, Harris, S, additional, Madden, J, additional, Cozens, K, additional, Little, L A, additional, Eichhorst, K, additional, Jones, J, additional, Moate, P, additional, McClement, C, additional, Pike, L, additional, Sinclair, D, additional, Wong, W L, additional, Shekhdar, J, additional, Eaton, R, additional, Shah, A, additional, Brindle, L, additional, Peebles, C, additional, Banerjee, A, additional, Dizdarevic, S, additional, Han, S, additional, Poon, F W, additional, Groves, A M, additional, Kurban, L, additional, Frew, A J, additional, Callister, M E, additional, Crosbie, P, additional, Gleeson, F V, additional, Karunasaagarar, K, additional, Kankam, O, additional, and Gilbert, F J, additional

Published
2016
Full Text
View/download PDF

17. 826P - Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE

Author

Sternberg, C.N., Tombal, B., Miller, K., Saad, F., Sartor, O., Sade, J.P., Logothetis, C., Bellmunt, J., Dizdarevic, S., Harshman, L.C., Logue, J., Baldari, S., Richardson, T., Bottomley, D., Schostak, M., Bayh, I., Kalinovsky, J., and Higano, C.

Published
2018
Full Text
View/download PDF

19. Combining statistical and machine learning based classifiers in the prediction of corporate failure

Author

Dizdarevic, S., Larrañaga Múgica, Pedro María, Sierra Araujo, Basilio, Lozano Alonso, José Antonio, Peña Sánchez, José María, Dizdarevic, S., Larrañaga Múgica, Pedro María, Sierra Araujo, Basilio, Lozano Alonso, José Antonio, and Peña Sánchez, José María

Abstract

This project presents the application of methods coming from Statistics as well as from an area of the Artificial Intelligence called Machine Learning, in the problem of the corporate failure prediction. The empirically compared paradigms applied to a sample of 120 Spanish companies,60 of which had gone bankrupt, and 60 had not, are Discriminant Analysis, Logistic Regression, Classification Trees, Rule Induction and Bayesian Networks. Two Artificial Intelligence techniques - Voting by Majority Principle and Bayesian Formalism -, are implemented in order to obtain prediction improvement over the single models that are compared. The predictor variables that gather the accountant information taken for every company over the three years previous to the date of survey are financial ratios.

Published
2005

20. Abstracts

Author

Dunet, V., primary, Dabiri, A., additional, Allenbach, G., additional, Goyeneche Achigar, A., additional, Waeber, B., additional, Feihl, F., additional, Heinzer, R., additional, Prior, J. O., additional, Van Velzen, J. E., additional, Schuijf, J. D., additional, De Graaf, F. R., additional, De Graaf, M. A., additional, Schalij, M. J., additional, Kroft, L. J., additional, De Roos, A., additional, Jukema, J. W., additional, Van Der Wall, E. E., additional, Bax, J. J., additional, Lankinen, E., additional, Saraste, A., additional, Noponen, T., additional, Klen, R., additional, Teras, M., additional, Kokki, T., additional, Kajander, S., additional, Pietila, M., additional, Ukkonen, H., additional, Knuuti, J., additional, Pazhenkottil, A. P., additional, Nkoulou, R. N., additional, Ghadri, J. R., additional, Herzog, B. A., additional, Buechel, R. R., additional, Kuest, S. M., additional, Wolfrum, M., additional, Gaemperli, O., additional, Husmann, L., additional, Kaufmann, P. A., additional, Andreini, D., additional, Pontone, G., additional, Mushtaq, S., additional, Antonioli, L., additional, Bertella, E., additional, Formenti, A., additional, Cortinovis, S., additional, Ballerini, G., additional, Fiorentini, C., additional, Pepi, M., additional, Koh, A. S., additional, Flores, J. S., additional, Keng, F. Y. J., additional, Tan, R. S., additional, Chua, T. S. J., additional, Annoni, A. D., additional, Tamborini, G., additional, Fusari, M., additional, Bartorelli, A. L., additional, Ewe, S. H., additional, Ng, A. C. T., additional, Delgado, V., additional, Schuijf, J., additional, Van Der Kley, F., additional, Colli, A., additional, De Weger, A., additional, Marsan, N. A., additional, Yiu, K. H., additional, Ng, A. C., additional, Timmer, S. A. J., additional, Knaapen, P., additional, Germans, T., additional, Dijkmans, P. A., additional, Lubberink, M., additional, Ten Berg, J. M., additional, Ten Cate, F. J., additional, Russel, I. K., additional, Lammertsma, A. A., additional, Van Rossum, A. C., additional, Wong, Y. Y., additional, Ruiter, G., additional, Raijmakers, P., additional, Van Der Laarse, W. J., additional, Westerhof, N., additional, Vonk-Noordegraaf, A., additional, Youssef, G., additional, Leung, E., additional, Wisenberg, G., additional, Marriot, C., additional, Williams, K., additional, Etele, J., additional, Dekemp, R. A., additional, Dasilva, J., additional, Birnie, D., additional, Beanlands, R. S. B., additional, Thompson, R. C., additional, Allam, A. H., additional, Wann, L. S., additional, Nureldin, A. H., additional, Adelmaksoub, G., additional, Badr, I., additional, Sutherland, M. L., additional, Sutherland, J. D., additional, Miyamoto, M. I., additional, Thomas, G. S., additional, Harms, H. J., additional, De Haan, S., additional, Huisman, M. C., additional, Schuit, R. C., additional, Windhorst, A. D., additional, Allaart, C., additional, Einstein, A. J., additional, Khawaja, T., additional, Greer, C., additional, Chokshi, A., additional, Jones, M., additional, Schaefle, K., additional, Bhatia, K., additional, Shimbo, D., additional, Schulze, P. C., additional, Srivastava, A., additional, Chettiar, R., additional, Moody, J., additional, Weyman, C., additional, Natale, D., additional, Bruni, W., additional, Liu, Y., additional, Ficaro, E., additional, Sinusas, A. J., additional, Peix, A., additional, Batista, E., additional, Cabrera, L. O., additional, Padron, K., additional, Rodriguez, L., additional, Sainz, B., additional, Mendoza, V., additional, Carrillo, R., additional, Fernandez, Y., additional, Mena, E., additional, Naum, A., additional, Bach-Gansmo, T., additional, Kleven-Madsen, N., additional, Biermann, M., additional, Johnsen, B., additional, Aase Husby, J., additional, Rotevatn, S., additional, Nordrehaug, J. E., additional, Schaap, J., additional, Kauling, R. M., additional, Post, M. C., additional, Rensing, B. J. W. M., additional, Verzijlbergen, J. F., additional, Sanchez, J., additional, Giamouzis, G., additional, Tziolas, N., additional, Georgoulias, P., additional, Karayannis, G., additional, Chamaidi, A., additional, Zavos, N., additional, Koutrakis, K., additional, Sitafidis, G., additional, Skoularigis, J., additional, Triposkiadis, F., additional, Radovanovic, S., additional, Djokovic, A., additional, Simic, D. V., additional, Krotin, M., additional, Savic-Radojevic, A., additional, Pljesa-Ercegovac, M., additional, Zdravkovic, M., additional, Saponjski, J., additional, Jelic, S., additional, Simic, T., additional, Eckardt, R., additional, Kjeldsen, B. J., additional, Andersen, L. I., additional, Haghfelt, T., additional, Grupe, P., additional, Johansen, A., additional, Hesse, B., additional, Pena, H., additional, Cantinho, G., additional, Wilk, M., additional, Srour, Y., additional, Godinho, F., additional, Zafrir, N., additional, Gutstein, A., additional, Mats, I., additional, Battler, A., additional, Solodky, A., additional, Sari, E., additional, Singh, N., additional, Vara, A., additional, Peters, A. M., additional, De Belder, A., additional, Nair, S., additional, Ryan, N., additional, James, R., additional, Dizdarevic, S., additional, Depuey, G., additional, Friedman, M., additional, Wray, R., additional, Old, R., additional, Babla, H., additional, Chuanyong, B., additional, Maddahi, J., additional, Tragardh Johansson, E., additional, Sjostrand, K., additional, Edenbrandt, L., additional, Aguade-Bruix, S., additional, Cuberas-Borros, G., additional, Pizzi, M. N., additional, Sabate-Fernandez, M., additional, De Leon, G., additional, Garcia-Dorado, D., additional, Castell-Conesa, J., additional, Candell-Riera, J., additional, Casset-Senon, D., additional, Edjlali-Goujon, M., additional, Alison, D., additional, Delhommais, A., additional, Cosnay, P., additional, Low, C. S., additional, Notghi, A., additional, O'brien, J., additional, Tweddel, A. C., additional, Bingham, N., additional, O Neil, P., additional, Harbinson, M., additional, Lindner, O., additional, Burchert, W., additional, Schaefers, M., additional, Marcassa, C., additional, Campini, R., additional, Calza, P., additional, Zoccarato, O., additional, Kisko, A., additional, Kmec, J., additional, Babcak, M., additional, Vereb, M., additional, Vytykacova, M., additional, Cencarik, J., additional, Gazdic, P., additional, Stasko, J., additional, Abreu, A., additional, Pereira, E., additional, Oliveira, L., additional, Colarinha, P., additional, Veloso, V., additional, Enriksson, I., additional, Proenca, G., additional, Delgado, P., additional, Rosario, L., additional, Sequeira, J., additional, Kosa, I., additional, Vassanyi, I., additional, Egyed, C. S., additional, Kozmann, G. Y., additional, Morita, S., additional, Nanasato, M., additional, Nanbu, I., additional, Yoshida, Y., additional, Hirayama, H., additional, Allam, A., additional, Sharef, A., additional, Shawky, I., additional, Farid, M., additional, Mouden, M., additional, Ottervanger, J. P., additional, Timmer, J. R., additional, De Boer, M. J., additional, Reiffers, S., additional, Jager, P. L., additional, Knollema, S., additional, Nasr, G. M., additional, Mohy Eldin, M., additional, Ragheb, M., additional, Casans-Tormo, I., additional, Diaz-Exposito, R., additional, Hurtado-Mauricio, F. J., additional, Ruano, R., additional, Diego, M., additional, Gomez-Caminero, F., additional, Albarran, C., additional, Martin De Arriba, A., additional, Rosero, A., additional, Lopez, R., additional, Martin Luengo, C., additional, Garcia-Talavera, J. R., additional, Laitinen, I. E. K., additional, Rudelius, M., additional, Weidl, E., additional, Henriksen, G., additional, Wester, H. J., additional, Schwaiger, M., additional, Pan, X. B., additional, Schindler, T., additional, Quercioli, A., additional, Zaidi, H., additional, Ratib, O., additional, Declerck, J. M., additional, Alexanderson Rosas, E., additional, Jacome, R., additional, Jimenez-Santos, M., additional, Romero, E., additional, Pena-Cabral, M. A., additional, Meave, A., additional, Gonzalez, J., additional, Rouzet, F., additional, Bachelet, L., additional, Alsac, J. M., additional, Suzuki, M., additional, Louedec, L., additional, Petiet, A., additional, Chaubet, F., additional, Letourneur, D., additional, Michel, J. B., additional, Le Guludec, D., additional, Aktas, A., additional, Cinar, A., additional, Yaman, G., additional, Bahceci, T., additional, Kavak, K., additional, Gencoglu, A., additional, Jimenez-Heffernan, A., additional, Sanchez De Mora, E., additional, Lopez-Martin, J., additional, Lopez-Aguilar, R., additional, Ramos, C., additional, Salgado, C., additional, Ortega, A., additional, Sanchez-Gonzalez, C., additional, Roa, J., additional, Tobaruela, A., additional, Nesterov, S. V., additional, Turta, O., additional, Maki, M., additional, Han, C., additional, Daou, D., additional, Tawileh, M., additional, Chamouine, S. O., additional, Coaguila, C., additional, Mariscal-Labrador, E., additional, Kisiel-Gonzalez, N., additional, De Araujo Goncalves, P., additional, Sousa, P. J., additional, Marques, H., additional, O'neill, J., additional, Pisco, J., additional, Cale, R., additional, Brito, J., additional, Gaspar, A., additional, Machado, F. P., additional, Roquette, J., additional, Martinez, M., additional, Melendez, G., additional, Kimura, E., additional, Ochoa, J. M., additional, Alessio, A. M., additional, Patel, A., additional, Lautamaki, R., additional, Bengel, F. M., additional, Bassingthwaighte, J. B., additional, Caldwell, J. H., additional, Rahbar, K., additional, Seifarth, H., additional, Schafers, M., additional, Stegger, L., additional, Spieker, T., additional, Hoffmeier, A., additional, Maintz, D., additional, Scheld, H., additional, Schober, O., additional, Weckesser, M., additional, Aoki, H., additional, Matsunari, I., additional, Kajinami, K., additional, Martin Fernandez, M., additional, Barreiro Perez, M., additional, Fernandez Cimadevilla, O. V., additional, Leon Duran, D., additional, Velasco Alonso, E., additional, Florez Munoz, J. P., additional, Luyando, L. H., additional, Templin, C., additional, Veltman, C. E., additional, Reiber, J. H. C., additional, Venuraju, S., additional, Yerramasu, A., additional, Atwal, S., additional, Lahiri, A., additional, Kunimasa, T., additional, Shiba, M., additional, Ishii, K., additional, Aikawa, J., additional, Kroner, E. S. J., additional, Ho, K. T., additional, Yong, Q. W., additional, Chua, K. C., additional, Panknin, C., additional, Roos, C. J., additional, Van Werkhoven, J. M., additional, Witkowska-Grzeslo, A. J., additional, Boogers, M. J., additional, Anand, D. V., additional, Dey, D., additional, Berman, D., additional, Mut, F., additional, Giubbini, R., additional, Lusa, L., additional, Massardo, T., additional, Iskandrian, A., additional, Dondi, M., additional, Sato, A., additional, Kakefuda, Y., additional, Ojima, E., additional, Adachi, T., additional, Atsumi, A., additional, Ishizu, T., additional, Seo, Y., additional, Hiroe, M., additional, Aonuma, K., additional, Kruk, M., additional, Pracon, R., additional, Kepka, C., additional, Pregowski, J., additional, Kowalewska, A., additional, Pilka, M., additional, Opolski, M., additional, Michalowska, I., additional, Dzielinska, Z., additional, Demkow, M., additional, Stoll, V., additional, Sabharwal, N., additional, Chakera, A., additional, Ormerod, O., additional, Fernandes, H., additional, Bernardes, M., additional, Martins, E., additional, Oliveira, P., additional, Vieira, T., additional, Terroso, G., additional, Oliveira, A., additional, Faria, T., additional, Ventura, F., additional, Pereira, J., additional, Fukuzawa, S., additional, Inagaki, M., additional, Sugioka, J., additional, Ikeda, A., additional, Okino, S., additional, Maekawa, J., additional, Uchiyama, T., additional, Kamioka, N., additional, Ichikawa, S., additional, Afshar, M., additional, Alvi, R., additional, Aguilar, N., additional, Ippili, R., additional, Shaqra, H., additional, Bella, J., additional, Bhalodkar, N., additional, Dos Santos, A., additional, Daicz, M., additional, Cendoya, L. O., additional, Marrero, H. G., additional, Casuscelli, J., additional, Embon, M., additional, Vera Janavel, G., additional, Duronto, E., additional, Gurfinkel, E. P., additional, Cortes, C. M., additional, Takeishi, Y., additional, Nakajima, K., additional, Yamasaki, Y., additional, Nishimura, T., additional, Hayes Brown, K., additional, Collado, F., additional, Alhaji, M., additional, Green, J., additional, Alexander, S., additional, Vashistha, R., additional, Jain, S., additional, Aldaas, F., additional, Shanes, J., additional, Doukky, R., additional, Ashikaga, K., additional, Akashi, Y. J., additional, Uemarsu, M., additional, Kamijima, R., additional, Yoneyama, K., additional, Omiya, K., additional, Miyake, Y., additional, Brodov, Y., additional, Raval, U., additional, Berezin, A., additional, Seden, V., additional, Koretskaya, E., additional, Panasenko, T. A., additional, Matsuo, S., additional, Kinuya, S., additional, Chen, J., additional, Van Bommel, R. J., additional, Van Der Hiel, B., additional, Dibbets-Schneider, P., additional, Garcia, E. V., additional, Rutten-Vermeltfoort, I., additional, Gevers, M. M. J., additional, Verhoeven, B., additional, Dijk Van, A. B., additional, Raaijmakers, E., additional, Raijmakers, P. G. H. M., additional, Engvall, J. E., additional, Gjerde, M., additional, De Geer, J., additional, Olsson, E., additional, Quick, P., additional, Persson, A., additional, Mazzanti, M., additional, Marini, M., additional, Pimpini, L., additional, Perna, G. P., additional, Marciano, C., additional, Gargiulo, P., additional, Galderisi, M., additional, D'amore, C., additional, Savarese, G., additional, Casaretti, L., additional, Paolillo, S., additional, Cuocolo, A., additional, Perrone Filardi, P., additional, Al-Amoodi, M., additional, Thompson, E. C., additional, Kennedy, K., additional, Bybee, K. A., additional, Mcghie, A. I., additional, O'keefe, J. H., additional, Bateman, T. M., additional, Van Der Palen, R. L. F., additional, Mavinkurve-Groothuis, A. M., additional, Bulten, B., additional, Bellersen, L., additional, Van Laarhoven, H. W. M., additional, Kapusta, L., additional, De Geus-Oei, L. F., additional, Pollice, P. P., additional, Bonifazi, M. B., additional, Pollice, F. P., additional, Clements, I. P., additional, Hodge, D. O., additional, Scott, C. G., additional, De Ville De Goyet, M., additional, Brichard, B., additional, Pirotte, T., additional, Moniotte, S., additional, Tio, R. A., additional, Elvan, A., additional, Dierckx, R. A. I. O., additional, Slart, R. H. J. A., additional, Furuhashi, T., additional, Moroi, M., additional, Hase, H., additional, Joki, N., additional, Masai, H., additional, Nakazato, R., additional, Fukuda, H., additional, Sugi, K., additional, Kryczka, K., additional, Kaczmarska, E., additional, Petryka, J., additional, Mazurkiewicz, L., additional, Ruzyllo, W., additional, Smanio, P., additional, Vieira Segundo, E., additional, Siqueira, M., additional, Kelendjian, J., additional, Ribeiro, J., additional, Alaca, J., additional, Oliveira, M., additional, Alves, F., additional, Peovska, I., additional, Maksimovic, J., additional, Vavlukis, M., additional, Kostova, N., additional, Pop Gorceva, D., additional, Majstorov, V., additional, Zdraveska, M., additional, Hussain, S., additional, Djearaman, M., additional, Hoey, E., additional, Morus, L., additional, Erinfolami, O., additional, Macnamara, A., additional, Opolski, M. P., additional, Witkowski, A., additional, Berti, V., additional, Ricci, F., additional, Gallicchio, R., additional, Acampa, W., additional, Cerisano, G., additional, Vigorito, C., additional, Sciagra', R., additional, Pupi, A., additional, Sliem, H., additional, Collado, F. M., additional, Schmidt, S., additional, Maheshwari, A., additional, Kiriakos, R., additional, Mwansa, V., additional, Ljubojevic, S., additional, Sedej, S., additional, Holzer, M., additional, Marsche, G., additional, Marijanski, V., additional, Kockskaemper, J., additional, Pieske, B., additional, Ricalde, A., additional, Alexanderson, G., additional, Mohani, A., additional, Khanna, P., additional, Sinusas, A., additional, Lee, F., additional, Pinas, V. A., additional, Van Eck-Smit, B. L. F., additional, Verberne, H. J., additional, De Bruin, C. M., additional, Guilhermina, G., additional, Jimenez-Angeles, L., additional, Ruiz De Jesus, O., additional, Yanez-Suarez, O., additional, Vallejo, E., additional, Reyes, E., additional, Chan, M., additional, Hossen, M. L., additional, Underwood, S. R., additional, Karu, A., additional, Bokhari, S., additional, Pineda, V., additional, Gracia-Sanchez, L. M., additional, Garcia-Burillo, A., additional, Zavadovskiy, K., additional, Lishmanov, Y. U., additional, Saushkin, W., additional, Kovalev, I., additional, Chernishov, A., additional, Annoni, A., additional, Tarkia, M., additional, Saanijoki, T., additional, Oikonen, V., additional, Savunen, T., additional, Green, M. A., additional, Strandberg, M., additional, Roivainen, A., additional, Gaeta, M. C., additional, Artigas, C., additional, Deportos, J., additional, Geraldo, L., additional, Flotats, A., additional, La Delfa, V., additional, Carrio, I., additional, Laarse, W. J., additional, Izquierdo Gomez, M. M., additional, Lacalzada Almeida, J., additional, Barragan Acea, A., additional, De La Rosa Hernandez, A., additional, Juarez Prera, R., additional, Blanco Palacios, G., additional, Bonilla Arjona, J. A., additional, Jimenez Rivera, J. J., additional, Iribarren Sarrias, J. L., additional, Laynez Cerdena, I., additional, Dedic, A., additional, Rossi, A., additional, Ten Kate, G. J. R., additional, Dharampal, A., additional, Moelker, A., additional, Galema, T. W., additional, Mollet, N., additional, De Feyter, P. J., additional, Nieman, K., additional, Trabattoni, D., additional, Broersen, A., additional, Frenay, M., additional, Boogers, M. M., additional, Kitslaar, P. H., additional, Dijkstra, J., additional, Annoni, D. A., additional, Muratori, M., additional, Johki, N., additional, Tokue, M., additional, Dharampal, A. S., additional, Weustink, A. C., additional, Neefjes, L. A. E., additional, Papadopoulou, S. L., additional, Chen, C., additional, Mollet, N. R. A., additional, Boersma, E. H., additional, Krestin, G. P., additional, Purvis, J. A., additional, Sharma, D., additional, Hughes, S. M., additional, Berman, D. S., additional, Taillefer, R., additional, Udelson, J., additional, Devine, M., additional, Lazewatsky, J., additional, Bhat, G., additional, Washburn, D., additional, Patel, D., additional, Mazurek, T., additional, Tandon, S., additional, Bansal, S., additional, Inzucchi, S., additional, Staib, L., additional, Davey, J., additional, Chyun, D., additional, Young, L., additional, Wackers, F., additional, Harbinson, M. T., additional, Wells, G., additional, Dougan, J., additional, Borges-Neto, S., additional, Phillips, H., additional, Farzaneh-Far, A., additional, Starr, Z., additional, Shaw, L. K., additional, Fiuzat, M., additional, O'connor, C., additional, Henzlova, M., additional, Duvall, W. L., additional, Levine, A., additional, Baber, U., additional, Croft, L., additional, Sahni, S., additional, Sethi, S., additional, Hermann, L., additional, Nureldin, A., additional, Gomaa, A., additional, Soliman, M. A. T., additional, Hany, H. A. R., additional, De Graaf, F., additional, Pazhenkottil, A., additional, Siebelink, H. M. J., additional, Reiber, J. H., additional, Ayub, M., additional, Naveed, T., additional, Azhar, M., additional, Van Tosh, A., additional, Faber, T. L., additional, Votaw, J. R., additional, Reichek, N., additional, Pulipati, B., additional, Palestro, C., additional, Nichols, K. J., additional, Okuda, K., additional, Kirihara, Y., additional, Ishikawa, T., additional, Taki, J., additional, Yoshita, M., additional, Yamada, M., additional, Salacata, A., additional, Keavey, S., additional, Chavarri, V., additional, Mills, J., additional, Nagaraj, H., additional, Bhambhani, P., additional, Kliner, D. E., additional, Soman, P., additional, Heo, J., additional, Iskandrian, A. E., additional, Jain, M., additional, Lin, B., additional, Walker, A., additional, Nkonde, C., additional, Bond, S., additional, Baskin, A., additional, Declerck, J., additional, Soto, M. E., additional, Mendoza, G., additional, Aguilar, M., additional, Williams, S. P., additional, Colice, G., additional, Mcardle, J. R., additional, Lankford, A., additional, Kajdasz, D. K., additional, Reed, C. R., additional, Angelini, L., additional, Angelozzi, F., additional, Ascoli, G., additional, Jacobson, A., additional, Lessig, H. J., additional, Gerson, M. C., additional, Cerqueira, M. D., additional, Narula, J., additional, Uematsu, M., additional, Kida, K., additional, Suzuki, K., additional, Bravo, P. E., additional, Fukushima, K., additional, Chaudhry, M., additional, Merrill, J., additional, Alonso Tello, A., additional, Rodriguez Palomares, J. F., additional, Marti Aguasca, G., additional, Aguade Bruix, S., additional, Aliaga, V., additional, Mahia, P., additional, Gonzalez-Alujas, T., additional, Candell, J., additional, Evangelista, A., additional, Mlynarski, R., additional, Mlynarska, A., additional, Sosnowski, M., additional, Zerahn, B., additional, Hasbak, P., additional, Mortensen, C. E., additional, Mathiesen, H. F., additional, Andersson, M., additional, Nielsen, D., additional, Ferreira Santos, L., additional, Ferreira, M. J., additional, Ramos, D., additional, Moreira, D., additional, Cunha, M. J., additional, Albuquerque, A., additional, Moreira, A., additional, Oliveira Santos, J., additional, Costa, G., additional, Providencia, L. A., additional, Arita, Y., additional, Kihara, S., additional, Mitsusada, N., additional, Miyawaki, M., additional, Ueda, H., additional, Hiraoka, H., additional, Matsuzawa, Y., additional, Askew, J., additional, O'connor, M., additional, Jordan, L., additional, Ruter, R., additional, Gibbons, R., additional, Miller, T., additional, Emmett, L., additional, Ng, A., additional, Sorensen, N., additional, Mansberg, R., additional, Kritharides, L., additional, Gonzalez, T., additional, Majmundar, H., additional, Coats, N. P., additional, Vernotico, S., additional, Doan, J. H., additional, Hernandez, T. M., additional, Evini, M., additional, Hepner, A. D., additional, Ip, T. K., additional, Chalela, W. A., additional, Falcao, A. M., additional, Azouri, L. O., additional, Ramires, J. A. F., additional, Meneghetti, J. C., additional, Manganelli, F., additional, Spadafora, M., additional, Varrella, P., additional, Peluso, G., additional, Sauro, R., additional, Di Lorenzo, E., additional, Rotondi, F., additional, Daniele, S., additional, Miletto, P., additional, Rijnders, A. J. M., additional, Hendrickx, B. W., additional, Van Der Bruggen, W., additional, America, Y. G. C. J., additional, Thorley, P. J., additional, Chowdhury, F. U., additional, Dickinson, C. J., additional, Sazonova, S. I., additional, Proskokova, I. Y. U., additional, Gusakova, A. M., additional, Minin, S. M., additional, Lishmanov, Y. U. B., additional, Saushkin, V. V., additional, Rodriguez, G., additional, Roffe, F., additional, Ilarraza, H., additional, Bialostozky, D., additional, Kitsiou, A. N., additional, Arsenos, P., additional, Tsiantis, I., additional, Charizopoulos, S., additional, Karas, S., additional, Vidal Perez, R. C., additional, Garrido, M., additional, Pubul, V., additional, Argibay, S., additional, Pena, C., additional, Pombo, M., additional, Ciobotaru, A. B., additional, Sanchez-Salmon, A., additional, Ruibal Morell, A., additional, Gonzalez-Juanatey, J. R., additional, Rodriguez-Gomez, E., additional, Martinez, B., additional, Pontillo, D., additional, Benvissuto, F., additional, Fiore Melacrinis, F., additional, Maccafeo, S., additional, Scabbia, E. V., additional, Schiavo, R., additional, Golzar, Y., additional, Gidea, C., additional, Golzar, J., additional, Pop-Gorceva, D., additional, Zdravkovska, M., additional, Stojanovski, S., additional, Georgievska-Ismail, L. J., additional, Katsikis, T., additional, Theodorakos, A., additional, Kouzoumi, A., additional, Koutelou, M., additional, Yoshimura, Y., additional, Toyama, T., additional, Hoshizaki, H., additional, Ohshima, S., additional, Inoue, M., additional, Suzuki, T., additional, Uitterdijk, A., additional, Dijkshoorn, M., additional, Van Straten, M., additional, Van Der Giessen, W. J., additional, Duncker, D. J., additional, Merkus, D., additional, Platsch, G., additional, Sunderland, J., additional, Tonge, C., additional, Arumugam, P., additional, Dey, T., additional, Wieczorek, H., additional, Bippus, R., additional, Romijn, R. L., additional, Backus, B. E., additional, Aach, T., additional, Lomsky, M., additional, Johansson, L., additional, Marving, J., additional, Svensson, S., additional, Pou, J. L., additional, Esteves, F. P., additional, Raggi, P., additional, Folks, R., additional, Keidar, Z., additional, Askew, J. W., additional, Verdes, L., additional, Campos, L., additional, Gulyaev, V., additional, Pankova, A., additional, Santos, J., additional, Carmona, S., additional, Henriksson, I., additional, Prata, A., additional, Carrageta, M., additional, Santos, A. I., additional, Yoshinaga, K., additional, Naya, M., additional, Katoh, C., additional, Manabe, O., additional, Yamada, S., additional, Iwano, H., additional, Chiba, S., additional, Tsutsui, H., additional, Tamaki, N., additional, Vassiliadis, I., additional, Despotopoulos, E., additional, Kaitozis, O., additional, Hatzistamatiou, E., additional, Thompson, R., additional, Hatch, J., additional, Zink, M., additional, Gu, B. S., additional, Bae, G. D., additional, Dae, C. M., additional, Min, G. H., additional, Chun, E. J., additional, Choi, S. I., additional, Al-Mallah, M., additional, Kassem, K., additional, Khawaja, O., additional, Goodman, D., additional, Lipkin, D., additional, Christiaens, L., additional, Bonnet, B., additional, Mergy, J., additional, Coisne, D., additional, Allal, J., additional, Dias Ferreira, N., additional, Leite, D., additional, Rocha, J., additional, Carvalho, M., additional, Caeiro, D., additional, Bettencourt, N., additional, Braga, P., additional, Gama Ribeiro, V., additional, Kristoffersen, U. S., additional, Lebech, A. M., additional, Gutte, H., additional, Ripa, R. S., additional, Wiinberg, N., additional, Petersen, C. L., additional, Jensen, G., additional, Kjaer, A., additional, Bai, C., additional, Conwell, R., additional, Folks, R. D., additional, Verdes-Moreiras, L., additional, Manatunga, D., additional, Jacobson, A. F., additional, Belzer, D., additional, Hasid, Y., additional, Rehling, M., additional, Poulsen, R. H., additional, Falborg, L., additional, Rasmussen, J. T., additional, Waehrens, L. N., additional, Heegaard, C. W., additional, Silvola, J. M. U., additional, Forsback, S., additional, Laine, J. O., additional, Heinonen, S., additional, Ylaherttuala, S., additional, Broisat, A., additional, Ruiz, M., additional, Goodman, N. C., additional, Dimastromatteo, J., additional, Glover, D. K., additional, Hyafil, F., additional, Blackwell, F., additional, Pavon-Djavid, G., additional, Sarda-Mantel, L., additional, Feldman, L. J., additional, Meddahi-Pelle, A., additional, Tsatkin, V., additional, Liu, Y.- H., additional, De Kemp, R., additional, Slomka, P. J., additional, Klein, R., additional, Germano, G., additional, Beanlands, R. S., additional, Rohani, A., additional, Akbari, V., additional, Groothuis, J. G. J., additional, Fransen, M., additional, Beek, A. M., additional, Brinckman, S. L., additional, Meijerink, M. R., additional, Hofman, M. B. M., additional, Van Kuijk, C., additional, Kogure, S., additional, Yamashita, E., additional, Murakami, J., additional, Kawaguchi, R., additional, Adachi, H., additional, Oshima, S., additional, Minin, S., additional, Popov, S., additional, Saushkina, Y. U., additional, Savenkova, G., additional, Lebedev, D., additional, Alexandridis, E., additional, Rovithis, D., additional, Parisis, C., additional, Sazonova, I., additional, Saushkin, V., additional, Chernov, V., additional, Zaabar, L., additional, Bahri, H., additional, Hadj Ali, S., additional, Sellem, A., additional, Slim, I., additional, El Kadri, N., additional, Slimen, H., additional, Hammami, H., additional, Lucic, S., additional, Peter, A., additional, Tadic, S., additional, Nikoletic, K., additional, Jung, R., additional, Lucic, M., additional, Tagil, K., additional, Jakobsson, D., additional, Svensson, S.- E., additional, Wollmer, P., additional, Leccisotti, L., additional, Indovina, L., additional, Paraggio, L., additional, Calcagni, M. L., additional, Giordano, A., additional, Kapitan, M., additional, Paolino, A., additional, Nunez, M., additional, Sweeny, J., additional, Kulkarni, N., additional, Guma, K., additional, Akashi, Y., additional, Takano, M., additional, Takai, M., additional, Koh, S., additional, Miyake, F., additional, Torun, N., additional, Durmus Altun, G., additional, Altun, A., additional, Kaya, E., additional, Saglam, H., additional, Matsuoka, D. T., additional, Sanchez, A., additional, Bartolozzi, C., additional, Padua, D., additional, Ponta, G., additional, Ponte, A., additional, Carneiro, A., additional, Thom, A., additional, Ashrafi, R., additional, Garg, P., additional, Davis, G., additional, Falcao, A., additional, Costa, M., additional, Bussolini, F., additional, Meneghetti, J. A. C., additional, Tobisaka, M., additional, Correia, E., additional, Jansen, J. W., additional, Van Der Vleuten, P. A., additional, Willems, T. P., additional, Zijlstra, F., additional, Sato, M., additional, Taniguchi, K., additional, Kurabayashi, M., additional, Pop Gjorcheva, D., additional, Zdraveska-Kochovska, M., additional, Moriwaki, K., additional, Kawamura, A., additional, Watanabe, K., additional, Omura, T., additional, Sakabe, S., additional, Seko, T., additional, Kasai, A., additional, Ito, M., additional, Obana, M., additional, Akasaka, T., additional, Hruska, C., additional, Truong, D., additional, Pletta, C., additional, Collins, D., additional, Tortorelli, C., additional, Rhodes, D., additional, El-Prince, M., additional, Martinez-Moeller, A., additional, Marinelli, M., additional, Weismueller, S., additional, Hillerer, C., additional, Jensen, B., additional, Nekolla, S. G., additional, Wakabayashi, H., additional, Tsukamoto, K., additional, Baker, S. M. E. A., additional, Sirajul Haque, K. M. H. S., additional, Siddique, A., additional, Krishna Banarjee, S., additional, Ahsan, A., additional, Rahman, F., additional, Mukhlesur Rahman, M., additional, Parveen, T., additional, Lutfinnessa, M., additional, Nasreen, F., additional, Sano, H., additional, Naito, S., additional, De Rimini, M. L., additional, Borrelli, G., additional, Baldascino, F., additional, Calabro, P., additional, Maiello, C., additional, Russo, A., additional, Amarelli, C., additional, Muto, P., additional, Danad, I., additional, Raijmakers, P. G., additional, Appelman, Y. E., additional, Hoekstra, O. S., additional, Marcus, J. T., additional, Boonstra, A., additional, Ryzhkova, D. V., additional, Kuzmina, T. V., additional, Borodina, O. S., additional, Trukshina, M. A., additional, Kostina, I. S., additional, Hommel, H., additional, Feuchtner, G., additional, Pachinger, O., additional, Friedrich, G., additional, Stel, A. M., additional, Deckers, J. W., additional, Gama, V., additional, Ciarka, A., additional, Neefjes, L. A., additional, Mollet, N. R., additional, Sijbrands, E. J., additional, Wilczek, J., additional, Llibre Pallares, C., additional, Abdul-Jawad Altisent, O., additional, Cuellar Calabria, H., additional, Mahia Casado, P., additional, Gonzalez-Alujas, M. T., additional, Evangelista Masip, A., additional, Garcia-Dorado Garcia, D., additional, Tekabe, Y., additional, Shen, X., additional, Li, Q., additional, Luma, J., additional, Weisenberger, D., additional, Schmidt, A. M., additional, Haubner, R., additional, Johnson, L., additional, Sleiman, L., additional, Thorn, S., additional, Hasu, M., additional, Thabet, M., additional, Dasilva, J. N., additional, Whitman, S. C., additional, Genovesi, D., additional, Giorgetti, A., additional, Gimelli, A., additional, Cannizzaro, G., additional, Bertagna, F., additional, Fagioli, G., additional, Rossi, M., additional, Bonini, R., additional, Marzullo, P., additional, Paterson, C. A., additional, Smith, S. A., additional, Small, A. D., additional, Goodfield, N. E. R., additional, Martin, W., additional, Nekolla, S., additional, Sherif, H., additional, Reder, S., additional, Yu, M., additional, Kusch, A., additional, Li, D., additional, Zou, J., additional, Lloyd, M. S., additional, Cao, K., additional, Motherwell, D. W., additional, Rice, A., additional, Mccurrach, G. M., additional, Cobbe, S. M., additional, Petrie, M. C., additional, Al Younis, I., additional, Van Der Wall, E., additional, Mirza, T., additional, Raza, M., additional, Hashemizadeh, H., additional, Santos, L., additional, Krishna, B. A., additional, Perna, F., additional, Lago, M., additional, Leo, M., additional, Pelargonio, G., additional, Bencardino, G., additional, Narducci, M. L., additional, Casella, M., additional, Bellocci, F., additional, Kirac, S., additional, Yaylali, O., additional, Serteser, M., additional, Yaylali, T., additional, Okizaki, A., additional, Urano, Y., additional, Nakayama, M., additional, Ishitoya, S., additional, Sato, J., additional, Ishikawa, Y., additional, Sakaguchi, M., additional, Nakagami, N., additional, Aburano, T., additional, Solav, S. V., additional, Bhandari, R., additional, Burrell, S., additional, Dorbala, S., additional, Bruno, I., additional, Caldarella, C., additional, Collarino, A., additional, Mattoli, M. V., additional, Stefanelli, A., additional, Cannarile, A., additional, Maggi, F., additional, Soukhov, V., additional, Bondarev, S., additional, Yalfimov, A., additional, Khan, M., additional, Priyadharshan, P. P., additional, Chandok, G., additional, Aziz, T., additional, Avison, M., additional, Smith, R. A., additional, Bulugahapitya, D. S., additional, Vakhtangadze, T., additional, Todua, F., additional, Baramia, M., additional, Antelava, G., additional, Roche, N.- C., additional, Paule, P., additional, Kerebel, S., additional, Gil, J.- M., additional, Fourcade, L., additional, Tzonevska, A., additional, Tzvetkov, K., additional, Atanasova, M., additional, Parvanova, V., additional, Chakarova, A., additional, Piperkova, E., additional, Kocabas, B., additional, Muderrisoglu, H., additional, Allaart, C. P., additional, Entok, E., additional, Simsek, S., additional, Akcay, B., additional, Ak, I., additional, Vardareli, E., additional, Stachura, M., additional, Kwasiborski, P. J., additional, Horszczaruk, G. J., additional, Komar, E., additional, Cwetsch, A., additional, Zraik, B., additional, Morales Demori, R., additional, Almeida, A. D. J., additional, Siqueira, M. E., additional, Vieira, E., additional, Balogh, I., additional, Kerecsen, G., additional, Marosi, E., additional, Szelid, Z. S., additional, Sattar, A., additional, Swadia, T., additional, Chattahi, J., additional, Qureshi, W., additional, Khalid, F., additional, Gonzalez, A., additional, Hechavarria, S., additional, Takamura, K., additional, Fujimoto, S., additional, Nakanishi, R., additional, Yamashina, S., additional, Namiki, A., additional, Yamazaki, J., additional, Koshino, K., additional, Hashikawa, Y., additional, Teramoto, N., additional, Hikake, M., additional, Ishikane, S., additional, Ikeda, T., additional, Iida, H., additional, Takahashi, Y., additional, Oriuchi, N., additional, Higashino, H., additional, Endo, K., additional, Mochizuki, T., additional, Murase, K., additional, Baali, A., additional, Moreno, R., additional, Chau, M., additional, Rousseau, H., additional, Nicoud, F., additional, Dolliner, P., additional, Brammen, L., additional, Steurer, G., additional, Traub-Weidinger, T., additional, Ubl, P., additional, Schaffarich, P., additional, Dobrozemsky, G., additional, Staudenherz, A., additional, Ozgen Kiratli, M., additional, Temelli, B., additional, Kanat, N. B., additional, Aksoy, T., additional, Slavich, G. A., additional, Piccoli, G., additional, Puppato, M., additional, Grillone, S., additional, Gasparini, D., additional, Dunet, V., additional, Perruchoud, S., additional, Poitry-Yamate, C., additional, Lepore, M., additional, Gruetter, R., additional, Pedrazzini, T., additional, Anselm, D., additional, Anselm, A., additional, Atkins, H., additional, Renaud, J., additional, Dekemp, R., additional, Burwash, I., additional, Guo, A., additional, Beanlands, R., additional, Glover, C., additional, Vilardi, I., additional, Zangheri, B., additional, Calabrese, L., additional, Romano, P., additional, Bruno, A., additional, Fernandez Cimadevilla, O. C., additional, Uusitalo, V. A., additional, Luotolahti, M., additional, Wendelin-Saarenhovi, M., additional, Sundell, J., additional, Raitakari, O., additional, Huidu, S., additional, Gadiraju, R., additional, Ghesani, M., additional, Uddin, Q., additional, Wosnitzer, B., additional, Takahashi, N., additional, Alhaj, E., additional, Legasto, A., additional, Abiri, B., additional, Elsaban, K., additional, El Khouly, T., additional, El Kammash, T., additional, Al Ghamdi, A., additional, Kyung Deok, B., additional, Bon Seung, K., additional, Sang Geun, Y., additional, Chang Min, D., additional, and Gwan Hong, M., additional

Published
2011
Full Text
View/download PDF

26. The appropriate whole-body index on which to base standardized uptake value in 2-deoxy-2-[18F] fludeoxyglucose PET.

Author

KERAMIDA, G., HUNTER, J., DIZDAREVIC, S., and PETERS, A. M.

Subjects
POSITRON emission tomography, RADIOPHARMACEUTICALS, LEAN body mass, BODY surface area, BODY mass index, THERAPEUTICS
Abstract

Objective: Tissue uptake of 2-deoxy-2-fluorine-18 fludeoxyglucose (18F-FDG) is routinely quantified as standardized uptake value (SUV), which in general is the fraction (F) of administered activity per millilitre of tissue multiplied by an index of body size, usually weight (W), i.e. F/ml × W = SUV or F/ml = SUV × (1/W). Other indices have been suggested as preferable to W, especially lean body mass (LBM) and body surface area (BSA), The second equation mentioned above shows that the reciprocal of the ideal index should correlate closely with F/ml and give a regression line through the origin. The purpose of this study was to determine which of these three indices best meets these criteria. Methods: Data were evaluated from 49 males and 51 females undergoing routine 18F-FDG positron emission tomography/CT. A 3 cm diameter region of interest was drawn over the liver and F/ml recorded. LBM and BSA were estimated from height and weight. Results: Based on all patients, the reciprocals of the three indices gave similar correlation coefficients with F/ml, but only 1/LBM gave regressions close to the origin. Intercepts were significantly higher for females for 1/W and 1/BSA, consistent with females having more body fat, but there was no significant difference with 1/LBM. Conclusion: LBM is the best index on which to base SUV because adipose tissue accumulates less 18F-FDG than other soft tissues. Advances in knowledge: The value of this study lies in its use of a novel, more rational approach than previously to confirm that SUV should be based on LBM. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

30. Genetic Algorithms for the Travelling Salesman Problem: a review of representations and operators

Author

Larrañaga Múgica, Pedro María, Kuijpers, C.M.H., Murga Gandasegui, Roberto Hugo, Inza Cano, Iñaki, Dizdarevic, S., Larrañaga Múgica, Pedro María, Kuijpers, C.M.H., Murga Gandasegui, Roberto Hugo, Inza Cano, Iñaki, and Dizdarevic, S.

Abstract

This paper is the result of a literature study carried out by the authors. It is a review of the different attempts made to solve the Travelling Salesman Problem with Genetic Algorithms. We present crossover and mutation operators, developed to tackle the Travelling Salesman Problem with Genetic Algorithms with different representations such as: binary representation, path representation, adjacency representation, ordinal representation and matrix representation. Likewise, we show the experimental results obtained with different standard examples using combination of crossover and mutation operators in relation with path representation.

Published
1999

33. Influence of computed tomography attenuation correction in myocardial perfusion imaging, in obese patients: Classification by sex and body mass index

Author

Stakhiv, O., Melo, I., Clarke, M., Aplin, M., Singh, N., Day, K., Dizdarevic, S., Jessop, M., Begley, P., Elisabete Carolino, Vieira, L., and Sousa, E.

Subjects
Attenuation correction, Myocardial perfusion imaging, Obesity, Computed tomography, IPL/2016/CardiaCor_ESTeSL, Body mass index
Abstract

Este trabalho foi financiado pelo Concurso Anual para Projetos de Investigação, Desenvolvimento, Inovação e Criação Artística (IDI&CA) 2016 do Instituto Politécnico de Lisboa. Código de referência: IPL/2016/CardiaCor_ESTeSL Four groups of 71 subjects 47 with body mass index (BMI) between 30 and 35 (27 Male (M1) and 20 Female (F1)) and 24 with BMI above 35 ( 13 Male (M2) and 11 Female (F2)) who underwent stress-rest , SPECT MPI of a two day protocol, by EANM guideline protocol, with and without the incorporation of the Attenuation correction by computed tomography (CTAC), for stress and rest separately. For perfusion percentage quantifications, the 5 walls model of the left ventricle (LV) was used: anterior (ANT), lateral (LAT), inferior (INF), septal (SEP) and apical (API), using the QGS/QPSTM software. For statistical evaluation, it was used the Friedman test. Statistically significant differences were found in comparison of studies with and without attenuation correction (AC) for: F1 in stress and rest studies respectively for LAT (p=0.006 and p=0.034), INF (p=0.000 and p=0.000) and in rest study for SEP (p=0.044) LV walls; F2 group of stress and rest studies respectively for INF (p=0.001 and p=0.008) walls; M1 group of stress and rest study respectively for LAT (p=0.000 and p=0.000), INF (p=0.000 and p=0.000) SEP (p=0.003 and p=0.001) walls and just in rest study for API (p=0.045) LV walls; M2 group of stress and rest studies respectively for INF (p=0.000 and p=0.000), LAT (p=0.020 and p=0.014) and in stress study for SEP (p=0.003) LV walls. The influence of CT-AC is bigger within the groups with BMI between 30 and 35. info:eu-repo/semantics/publishedVersion

39. Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study.

Author

O'Sullivan JM, Heinrich D, Castro E, George S, Dizdarevic S, Baldari S, Essler M, Jong IJ, Lastoria S, Hammerer PG, Tombal B, James ND, Meltzer J, Sandström P, and Sartor O

Abstract

Background: Alkaline phosphatase (ALP) declines and pain responses can occur during radium-223 ( 223 Ra) treatment, but their association with treatment outcomes is unclear., Methods: For patients with metastatic castration-resistant prostate cancer treated with 223 Ra in the REASSURE study, we investigated whether ALP decline (Week 12) and/or pain response (during treatment) are associated with improved overall survival (OS). The Brief Pain Inventory-Short Form (BPI-SF) was used to assess pain at baseline and pain response (in patients with baseline BPI-SF score ≥2)., Results: Of 785 patients with baseline and Week 12 ALP measurements, 779 were eligible for the OS analyses. Overall, 80% of patients had an ALP decline. Median OS was longer in patients with than without an ALP decline (18.1 versus 14.2 months; HR 0.74; 95% CI 0.60-0.92). In patients with an ALP decline, there was no clear OS difference between those with versus without a pain response. For patients without ALP decline, median OS was longer in those with versus without a pain response (16.2 versus 10.9 months; HR 0.50; 95% CI 0.32-0.77)., Conclusions: Decreases in ALP and/or pain during 223 Ra treatment are associated with improved OS. This may help support clinical decisions., Clinical Trial Registration: ClinicalTrials.gov identifier NCT02141438. Analyses from the radium-223 REASSURE global study suggest that declines in alkaline phosphatase and pain during treatment may predict longer survival in patients with advanced prostate cancer and may help doctors make decisions with their patients., Competing Interests: Competing interests: JMO’S reports consulting or advisory roles for Bayer, Janssen, Astellas Pharma, Sanofi and Novartis. Speakers’ Bureau from Bayer, Janssen and Novartis. His institution has received research funding from Bayer. DH reports consulting or advisory roles from Astellas Pharma, Bayer, Eisai, Ipsen, Organon and Pfizer. Honoraria from Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, EUSA, Ferring, Ipsen, Janssen-Cilaq, Merck, Sharp & Dome (MSD), Novartis, Novo Nordisk, Sanofi and Pfizer. His institution has received research funding from AstraZeneca, Bristol-Myers Squibb, Eisai, Janssen-Cilaq, MSD, Pfizer and Roche. EC reports consulting or advisory roles from Bayer, Janssen, AstraZeneca, Astellas Pharma, Merck, Pfizer and MSD Oncology. Travel, accommodation or expenses from Bayer, Janssen, Roche, Astellas Pharma and AstraZeneca. Expert testimony from Pfizer. Honoraria from Astellas Pharma, Janssen-Cilag, AstraZeneca, Bayer, Pfizer, Roche and Clovis Oncology. Her institution has received research funding from AstraZeneca, Bayer, Janssen and SYNLAB. SG reports consulting or advisory roles from Bristol-Myers Squibb, Bayer, Pfizer, Exelixis, Corvus Pharmaceuticals, Sanofi/Genzyme, EMD Serono, Seattle Genetics/Astellas, Eisai, Merck, AVEO, AstraZeneca and QED Therapeutics. His institution has received research funding from Pfizer, Merck, Agensys, Novartis, Bristol-Myers Squibb, Bayer, Eisai, Seattle Genetics/Astellas, Calithera Biosciences, Corvus Pharmaceuticals, Surface Oncology, Exelixis, Aravive, Aveo and Gilead Sciences. SD reports consulting or advisory roles from GE Healthcare, Bayer and Advanced Accelerator Applications. SB has no conflicts of interest to declare. ME reports consulting or advisory roles from Advanced Accelerator Applications, Bayer and Ipsen. Travel, accommodation or expenses from Ipsen. IJdeJ reports speakers’ bureau from AstraZeneca. Travel, accommodation or expenses from Bayer. SL has no conflicts of interest to declare. PGH reports consulting or advisory roles from Bayer, Amgen, Novartis, Janssen, AstraZeneca, Astellas Pharma, Merck, Pfizer, Takeda and MSD Oncology. Travel, accommodation or expenses from Bayer, Janssen, Astellas Pharma and Pfizer. BT reports consulting or advisory roles from Astellas Pharma, Bayer, Ferring, Janssen, Takeda, Steba Biotech, Sanofi, Myovant Sciences, Pfizer/Astellas. Speakers’ bureau from Amgen, Janssen and Astellas Pharma. Travel, accommodation or expenses from Amgen, Astellas Pharma, Bayer, Ferring, Janssen and Sanofi. Expert testimony from Tookad. Honoraria from Amgen, Astellas Pharma, Bayer, Ferring, Sanofi, Janssen, Pfizer and Myovant Sciences. His institution has received research funding from Ferring. NDJ reports consulting or advisory roles from Sanofi, Bayer, Astellas Pharma, Janssen, Clovis Oncology, EUSA pharma and Pfizer. Speakers’ bureau from Pierre Fabre, Ferring, Sanofi, Astellas Pharma, Janssen Oncology, Merck and AstraZeneca. Travel, accommodation or expenses from Sanofi and Janssen. Honoraria from Sanofi, Bayer, Janssen and Astellas Pharma. His institution has received research funding from Janssen, Astellas Pharma, Pfizer, Sanofi, Novartis and AstraZeneca. JM is an employee of Bayer and reports stock and other ownership interests from Bayer (myself and an immediate family member), Pfizer (myself and an immediate family member), Lilly (myself and an immediate family member). PS is an employee of Bayer. OS reports consulting or advisory roles from Bayer, Sanofi, AstraZeneca, Dendreon, Constellation Pharmaceuticals, Advanced Accelerator Applications, Pfizer, Bristol-Myers Squibb, Bavarian Nordic, EMD Serono, Astellas Pharma, Progenics, Blue Earth Diagnostics, Myovant Sciences, Myriad Genetics, Novartis, Clarity Pharmaceuticals, Fusion Pharmaceuticals, Isotopen Technologien, Janssen, Noxopharm, Clovis Oncology, Noria Therapeutics, Point Biopharma, TeneoBio, Telix Pharmaceuticals and Theragnostics. Travel, accommodation or expenses from Bayer, Johnson & Johnson, Sanofi, AstraZeneca and Progenics. Expert testimony from Sanofi. Stock and other ownership interests from Lilly, GlaxoSmithKline, AbbVie, Cardinal Health, United Health Group, PSMA Therapeutics, Clarity Pharmaceuticals, Noria Therapeutics and Clovis Oncology. His institution has received research funding from Bayer, Sanofi, Endocyte, Merck, InVitae, Constellation Pharmaceuticals, Advanced Accelerator Applications, AstraZeneca and Dendreon. He has received research funding from SOTIO and Janssen. Ethics approval and consent to participate: The conduct of REASSURE complies with the principles of the Declaration of Helsinki and the guidelines and regulations of the European Medicines Agency, US Food and Drug Administration, applicable local laws and regulations, and International Conference on Harmonisation Good Clinical Practice. All patients provided signed informed consent, and approvals were obtained from ethical committees or institutional review boards in the participating countries (a list of the ethics committees/institutional review boards that approved the study is provided in Supplementary Table 3)., (© 2025. The Author(s).)

Published
2025
Full Text
View/download PDF

40. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).

Author

Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandström P, Verholen F, Tombal B, and Sartor O

Subjects
Humans, Male, Aged, Middle Aged, Prospective Studies, Aged, 80 and over, Docetaxel therapeutic use, Docetaxel administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant pathology, Prostatic Neoplasms, Castration-Resistant radiotherapy, Radium therapeutic use, Radium adverse effects, Taxoids therapeutic use, Taxoids adverse effects
Abstract

Background: Radium-223 and taxane chemotherapy each improve survival of patients with metastatic castration-resistant prostate cancer (mCRPC). Whether the radium-223-taxane sequence could extend survival without cumulative toxicity was explored., Methods: The global, prospective, observational REASSURE study (NCT02141438) assessed real-world safety and effectiveness of radium-223 in patients with mCRPC. Using data from the prespecified second interim analysis (data cutoff, March 20, 2019), hematologic events and overall survival (OS) were evaluated in patients who were chemotherapy-naive at radium-223 initiation and subsequently received taxane chemotherapy starting ≤90 days ("immediate") or >90 days ("delayed") after the last radium-223 dose., Results: Following radium-223 therapy, 182 patients received docetaxel (172 [95%]) and/or cabazitaxel (44 [24%]); 34 patients (19%) received both. Seventy-three patients (40%) received immediate chemotherapy and 109 patients (60%) received delayed chemotherapy. Median time from last radium-223 dose to first taxane cycle was 3.6 months (range, 0.3-28.4). Median duration of first taxane was 3.7 months (range, 0-22.0). Fourteen patients (10 in the immediate and four in the delayed subgroup) had grade 3/4 hematologic events during taxane chemotherapy, including neutropenia in two patients in the delayed subgroup and thrombocytopenia in one patient in each subgroup. Median OS was 24.3 months from radium-223 initiation and 11.8 months from start of taxane therapy., Conclusions: In real-world clinical practice settings, a heterogeneous population of patients who received sequential radium-223-taxane therapy had a low incidence of hematologic events, with a median survival of 1 year from taxane initiation. Thus, taxane chemotherapy is a feasible option for those who progress after radium-223., Clinical Trial Registration: ClinicalTrials.gov identifier NCT02141438., Plain Language Summary: Radium-223 and chemotherapy are treatment options for metastatic prostate cancer, which increase survival but may affect production of blood cells as a side effect. We wanted to know what would happen if patients received chemotherapy after radium-223. Among the 182 men treated with radium-223 who went on to receive chemotherapy, only two men had severe side effects affecting white blood cell production (neutropenia) during chemotherapy. On average, the 182 men lived for 2 years after starting radium-223 and 1 year after starting chemotherapy. In conclusion, patients may benefit from chemotherapy after radium-223 treatment without increasing the risk of side effects., (© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)

Published
2024
Full Text
View/download PDF

42. The British nuclear medicine research strategy - the framework.

Author

Dizdarevic S, Mccready VR, Blower PJ, Vöö SA, Wadsley J, McGowan DR, Roldão Pereira L, Eccles A, Prakash VS, Abreu C, Jessop M, and Weston CJ

Subjects
Humans, Research Design, Radionuclide Imaging, Radioisotopes, Nuclear Medicine
Abstract

The British Nuclear Medicine Society (BNMS) has developed a Research Strategy framework led by the Research Champions of the BNMS and overseen by the BNMS Research and Innovation Committee. The objectives of the Research Strategy are to improve translation of cutting-edge nuclear medicine research from bench to bedside, the implementation of state-of-the-art multimodality technologies and to enhance multicentre radionuclide research in the UK. It strives to involve patients and the public in radionuclide research and to contribute to and work with the multi-professional national and international organisations involved in research with an ultimate aim to improve nuclear medicine services, and patients' outcomes and care., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

43. Association between body mass index (BMI) and [ 123 I]Ioflupane (DaTSCAN) availabilities in patients with parkinsonism using single-photon emission computed tomography-computed tomography (SPECT-CT).

Author

Parekh P, Begley P, Jessop M, Aplin M, Missir E, McMeekin H, Raczek G, Singh N, and Dizdarevic S

Abstract

Aim: [ 123 I]Ioflupane (DaTSCAN) has a high binding affinity to the dopamine (DA) transporter (DaT) and tenfold less affinity to serotonin (5-HT) transporter (SERT). Both neurotransmitters are considered to contribute to body weight regulation. This study assesses the association between body mass index (BMI) and DaTSCAN availability in brain., Method: Scans from 74 consecutive patients who had undergone DaTSCAN single-photon emission computed tomography-computed tomography (SPECT-CT) were used to obtain semi- and absolute quantitative data in several volumes of interest (VOIs). Relative semi-quantitative specific binding ratios (SBRs) from Chang attenuated SPECT were obtained from GE DaTQUANT. Absolute normalised concentration (NC) was calculated from attenuation/scatter corrected SPECT-CT images, using an adapted version of the EARL Ltd (European Association of Nuclear Medicine (EANM) Research 4 Life) template. Scans were subdivided into either degenerative parkinsonism (abnormal = 49), borderline (n = 14) or scan without evidence of dopaminergic deficit (SWEDD = 11) using visual assessment and SBR values by two nuclear medicine consultants., Results: SBRs did not correlate with BMI. However, NC values correlated negatively in the entire cohort, with the strongest correlation in the frontal (r = - 0.649. p = 0.000), occipital (r = - 0.555, p = 0.000) regions and pons (r = - 0.555, p = 0.000). In the abnormal (n = 49) and SWEDD group (n = 11), NC of the frontal region was the most correlated with BMI (r = - 0.570, p = 0.000; r = - 0.813, p = 0.002, respectively). In the borderline group (n = 14), the left posterior putamen displayed the strongest correlation (r = - 0.765, p = 0.001)., Conclusion: Absolute NC values demonstrate a strong inverse correlation with BMI, strongest in the extrastriatal regions. Due to the predominately non-overlapping distribution of DaT and SERT, this study suggests greater involvement of SERT in obesity with possible interplay with DA transmission., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

45. Quantitative [123]I-Ioflupane DaTSCAN single-photon computed tomography-computed tomography in Parkinsonism.

Author

Missir E, Begley P, Jessop M, Singh N, Aplin M, McMeekin H, Parekh P, Raczek M, and Dizdarevic S

Subjects
Humans, Tomography, X-Ray Computed, Tomography, Emission-Computed, Single-Photon methods, Dopamine Plasma Membrane Transport Proteins metabolism, Neurodegenerative Diseases, Parkinsonian Disorders diagnostic imaging, Nortropanes metabolism
Abstract

Aim: [123]I-Ioflupane (DaTSCAN) binds to the presynaptic dopamine transporter (DAT) and with a lower affinity to the serotonin transporter (SERT). We aimed to develop a novel method to quantify absolute uptake in the striatal (predominantly DAT binding) and extra-striatal regions (mainly SERT binding) using single-photon computed tomography-computed tomography (SPECT-CT) DaTSCAN and to improve DaTSCAN image quality., Method: Twenty-six patients with Parkinsonism underwent DaTSCAN SPECT-CT prospectively. The scans were visually analyzed independently by two experienced reporters. Specific binding ratios (SBRs) from Chang attenuation corrected SPECT were obtained using GE DaTQuant. Normalized concentrations and specific uptakes (NSU) from measured attenuation and modelled scatter-corrected SPECT-CT were obtained using HERMES Hybrid Recon and Affinity and modified EARL volumes of interest., Results: Striatal NSU and SBR positively correlate ( R  = 0.65-0.88, P  = 0.00). SBR, normalized concentrations, and NSU box plots differentiated between scans without evidence of dopaminergic deficit and abnormal scans. Interestingly, body weight inversely correlated with normalized concentrations values in extra-striatal regions [frontal ( R  = 0.81, P  = 0.00); thalamus ( R  = 0.58, P  = 0.00); occipital ( R  = 0.69, P  = 0.00)] and both caudate nuclei [ R  = 0.42, P  = 0.03 (Right), R  = 0.52, P  = 0.01 (Left)]. Both reporters noted improved visual quality of SPECT-CT versus SPECT images for all scans., Conclusion: DaTSCAN SPECT-CT resulted in more accurate quantification, improved image quality, and enabled absolute quantification of extra-striatal regions. More extensive studies are required to establish the full value of absolute quantification for diagnosis and monitoring the progression of neurodegenerative disease, to assess an interplay between DAT and SERT, and to verify whether serotonin and DATs are potentially dysfunctional in obesity., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

46. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.

Author

Barritt AW, Das E, Morley N, Seymour M, Saha R, Vera J, Vundavalli S, Dizdarevic S, Nicholas R, Berger JR, and Fisniku LK

Subjects
Male, Humans, Middle Aged, Fingolimod Hydrochloride adverse effects, Magnetic Resonance Imaging, Natalizumab adverse effects, Leukoencephalopathy, Progressive Multifocal chemically induced, Leukoencephalopathy, Progressive Multifocal diagnostic imaging, Leukoencephalopathy, Progressive Multifocal drug therapy, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis drug therapy, JC Virus
Abstract

A 62-year-old man with relapsing-remitting multiple sclerosis developed progressive multifocal leukencephalopathy (PML) after 6 years on fingolimod. The fingolimod was immediately discontinued and preexisting mirtazepine increased. Three weeks later, with brain magnetic resonance imaging (MRI) appearances worsening and cerebrospinal fluid (CSF) JC virus (JCV) titres increasing, maraviroc was introduced. At 6 weeks, subtle punctate contrast enhancement raised the possibility of immune reconstitution inflammatory syndrome (IRIS), followed by a single focal-to-generalised tonic clonic seizure and a further deterioration in clinical disability. Mefloquine was commenced alongside three doses of pembrolizumab administered a month apart. Serial CSF examinations and several imaging modalities including spectroscopy and fused FDG-PET-MRI (18F-fluoro-deoxy-glucose-positron emission tomography-magnetic resonance imaging) were used to help distinguish between PML, PML-IRIS and rebound MS activity and guide optimal management at each stage. A handful of small, enhancing ovoid lesions developed between the first two doses of pembrolizumab, probably representative of a mild rebound phenomenon. A sustained improvement became obvious thereafter with CSF JCV-DNA undetectable 16 weeks following fingolimod withdrawal. To our knowledge, this is the first case of combined therapy and use of pembrolizumab in a fingolimod-associated PML.

Published
2023
Full Text
View/download PDF

47. Protocol for a MULTI-centre feasibility study to assess the use of 99m Tc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study).

Author

Warren H, Wagner T, Gorin MA, Rowe S, Holman BF, Pencharz D, El-Sheikh S, Barod R, Patki P, Mumtaz F, Bex A, Kasivisvanathan V, Moore CM, Campain N, Cartledge J, Scarsbrook A, Hassan F, O'Brien TS, Stewart GD, Mendichovszky I, Dizdarevic S, Alanbuki A, Wildgoose WH, Wah T, Vindrola-Padros C, Pizzo E, Dehbi HM, Lorgelly P, Gurusamy K, Emberton M, and Tran MGB

Subjects
Humans, Feasibility Studies, Multicenter Studies as Topic, Prospective Studies, Radiopharmaceuticals, Technetium Tc 99m Sestamibi, Tomography, X-Ray Computed, Kidney Neoplasms diagnostic imaging, Tomography, Emission-Computed, Single-Photon
Abstract

Introduction: The incidence of renal tumours is increasing and anatomic imaging cannot reliably distinguish benign tumours from renal cell carcinoma. Up to 30% of renal tumours are benign, with oncocytomas the most common type. Biopsy has not been routinely adopted in many centres due to concerns surrounding non-diagnostic rate, bleeding and tumour seeding. As a result, benign masses are often unnecessarily surgically resected. 99m Tc-sestamibi SPECT/CT has shown high diagnostic accuracy for benign renal oncocytomas and other oncocytic renal neoplasms of low malignant potential in single-centre studies. The primary aim of MULTI-MIBI is to assess feasibility of a multicentre study of 99m Tc-sestamibi SPECT/CT against a reference standard of histopathology from surgical resection or biopsy. Secondary aims of the study include obtaining estimates of 99m Tc-sestamibi SPECT/CT sensitivity and specificity and to inform the design and conduct of a future definitive trial., Methods and Analysis: A feasibility prospective multicentre study of participants with indeterminate, clinical T1 renal tumours to undergo 99m Tc-sestamibi SPECT/CT (index test) compared with histopathology from biopsy or surgical resection (reference test). Interpretation of the index and reference tests will be blinded to the results of the other. Recruitment rate as well as estimates of sensitivity, specificity, positive and negative predictive value will be reported. Semistructured interviews with patients and clinicians will provide qualitative data to inform onward trial design and delivery. Training materials for 99m Tc-sestamibi SPECT/CT interpretation will be developed, assessed and optimised. Early health economic modelling using a decision analytic approach for different diagnostic strategies will be performed to understand the potential cost-effectiveness of 99m Tc-sestamibi SPECT/CT., Ethics and Dissemination: Ethical approval has been granted (UK HRA REC 20/YH/0279) protocol V.5.0 dated 21/6/2022. Study outputs will be presented and published nationally and internationally., Trial Registration Number: ISRCTN12572202., Competing Interests: Competing interests: GDS has received educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and CMR Surgical; Travel expenses from Pfizer and Speaker fees from Pfizer. SD provides educational consultancy for GE Healthcare, Bayer, AAA and AVAANT diagnostics., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.)

Published
2023
Full Text
View/download PDF

48. Comparative accuracy and cost-effectiveness of dynamic contrast-enhanced CT and positron emission tomography in the characterisation of solitary pulmonary nodules.

Author

Gilbert FJ, Harris S, Miles KA, Weir-McCall JR, Qureshi NR, Rintoul RC, Dizdarevic S, Pike L, Sinclair D, Shah A, Eaton R, Jones J, Clegg A, Benedetto V, Hill J, Cook A, Tzelis D, Vale L, Brindle L, Madden J, Cozens K, Little L, Eichhorst K, Moate P, McClement C, Peebles C, Banerjee A, Han S, Poon FW, Groves AM, Kurban L, Frew A, Callister MEJ, Crosbie PA, Gleeson FV, Karunasaagarar K, Kankam O, and George S

Subjects
Humans, Female, Male, Positron Emission Tomography Computed Tomography methods, Cost-Benefit Analysis, Prospective Studies, Fluorodeoxyglucose F18, Tomography, X-Ray Computed methods, Positron-Emission Tomography methods, Radiopharmaceuticals, Sensitivity and Specificity, Solitary Pulmonary Nodule diagnostic imaging, Lung Neoplasms diagnostic imaging
Abstract

Introduction: Dynamic contrast-enhanced CT (DCE-CT) and positron emission tomography/CT (PET/CT) have a high reported accuracy for the diagnosis of malignancy in solitary pulmonary nodules (SPNs). The aim of this study was to compare the accuracy and cost-effectiveness of these., Methods: In this prospective multicentre trial, 380 participants with an SPN (8-30 mm) and no recent history of malignancy underwent DCE-CT and PET/CT. All patients underwent either biopsy with histological diagnosis or completed CT follow-up. Primary outcome measures were sensitivity, specificity and overall diagnostic accuracy for PET/CT and DCE-CT. Costs and cost-effectiveness were estimated from a healthcare provider perspective using a decision-model., Results: 312 participants (47% female, 68.1±9.0 years) completed the study, with 61% rate of malignancy at 2 years. The sensitivity, specificity, positive predictive value and negative predictive values for DCE-CT were 95.3% (95% CI 91.3 to 97.5), 29.8% (95% CI 22.3 to 38.4), 68.2% (95% CI 62.4% to 73.5%) and 80.0% (95% CI 66.2 to 89.1), respectively, and for PET/CT were 79.1% (95% CI 72.7 to 84.2), 81.8% (95% CI 74.0 to 87.7), 87.3% (95% CI 81.5 to 91.5) and 71.2% (95% CI 63.2 to 78.1). The area under the receiver operator characteristic curve (AUROC) for DCE-CT and PET/CT was 0.62 (95% CI 0.58 to 0.67) and 0.80 (95% CI 0.76 to 0.85), respectively (p<0.001). Combined results significantly increased diagnostic accuracy over PET/CT alone (AUROC=0.90 (95% CI 0.86 to 0.93), p<0.001). DCE-CT was preferred when the willingness to pay per incremental cost per correctly treated malignancy was below £9000. Above £15 500 a combined approach was preferred., Conclusions: PET/CT has a superior diagnostic accuracy to DCE-CT for the diagnosis of SPNs. Combining both techniques improves the diagnostic accuracy over either test alone and could be cost-effective., Trial Registration Number: NCT02013063., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2022
Full Text
View/download PDF

49. Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling.

Author

Gilbert FJ, Harris S, Miles KA, Weir-McCall JR, Qureshi NR, Rintoul RC, Dizdarevic S, Pike L, Sinclair D, Shah A, Eaton R, Clegg A, Benedetto V, Hill JE, Cook A, Tzelis D, Vale L, Brindle L, Madden J, Cozens K, Little LA, Eichhorst K, Moate P, McClement C, Peebles C, Banerjee A, Han S, Poon FW, Groves AM, Kurban L, Frew AJ, Callister ME, Crosbie P, Gleeson FV, Karunasaagarar K, Kankam O, and George S

Subjects
Aged, Cost-Benefit Analysis, Humans, Positron-Emission Tomography, Technology Assessment, Biomedical, Tomography, X-Ray Computed, Solitary Pulmonary Nodule diagnostic imaging
Abstract

Background: Current pathways recommend positron emission tomography-computerised tomography for the characterisation of solitary pulmonary nodules. Dynamic contrast-enhanced computerised tomography may be a more cost-effective approach., Objectives: To determine the diagnostic performances of dynamic contrast-enhanced computerised tomography and positron emission tomography-computerised tomography in the NHS for solitary pulmonary nodules. Systematic reviews and a health economic evaluation contributed to the decision-analytic modelling to assess the likely costs and health outcomes resulting from incorporation of dynamic contrast-enhanced computerised tomography into management strategies., Design: Multicentre comparative accuracy trial., Setting: Secondary or tertiary outpatient settings at 16 hospitals in the UK., Participants: Participants with solitary pulmonary nodules of ≥ 8 mm and of ≤ 30 mm in size with no malignancy in the previous 2 years were included., Interventions: Baseline positron emission tomography-computerised tomography and dynamic contrast-enhanced computer tomography with 2 years' follow-up., Main Outcome Measures: Primary outcome measures were sensitivity, specificity and diagnostic accuracy for positron emission tomography-computerised tomography and dynamic contrast-enhanced computerised tomography. Incremental cost-effectiveness ratios compared management strategies that used dynamic contrast-enhanced computerised tomography with management strategies that did not use dynamic contrast-enhanced computerised tomography., Results: A total of 380 patients were recruited (median age 69 years). Of 312 patients with matched dynamic contrast-enhanced computer tomography and positron emission tomography-computerised tomography examinations, 191 (61%) were cancer patients. The sensitivity, specificity and diagnostic accuracy for positron emission tomography-computerised tomography and dynamic contrast-enhanced computer tomography were 72.8% (95% confidence interval 66.1% to 78.6%), 81.8% (95% confidence interval 74.0% to 87.7%), 76.3% (95% confidence interval 71.3% to 80.7%) and 95.3% (95% confidence interval 91.3% to 97.5%), 29.8% (95% confidence interval 22.3% to 38.4%) and 69.9% (95% confidence interval 64.6% to 74.7%), respectively. Exploratory modelling showed that maximum standardised uptake values had the best diagnostic accuracy, with an area under the curve of 0.87, which increased to 0.90 if combined with dynamic contrast-enhanced computerised tomography peak enhancement. The economic analysis showed that, over 24 months, dynamic contrast-enhanced computerised tomography was less costly (£3305, 95% confidence interval £2952 to £3746) than positron emission tomography-computerised tomography (£4013, 95% confidence interval £3673 to £4498) or a strategy combining the two tests (£4058, 95% confidence interval £3702 to £4547). Positron emission tomography-computerised tomography led to more patients with malignant nodules being correctly managed, 0.44 on average (95% confidence interval 0.39 to 0.49), compared with 0.40 (95% confidence interval 0.35 to 0.45); using both tests further increased this (0.47, 95% confidence interval 0.42 to 0.51)., Limitations: The high prevalence of malignancy in nodules observed in this trial, compared with that observed in nodules identified within screening programmes, limits the generalisation of the current results to nodules identified by screening., Conclusions: Findings from this research indicate that positron emission tomography-computerised tomography is more accurate than dynamic contrast-enhanced computerised tomography for the characterisation of solitary pulmonary nodules. A combination of maximum standardised uptake value and peak enhancement had the highest accuracy with a small increase in costs. Findings from this research also indicate that a combined positron emission tomography-dynamic contrast-enhanced computerised tomography approach with a slightly higher willingness to pay to avoid missing small cancers or to avoid a 'watch and wait' policy may be an approach to consider., Future Work: Integration of the dynamic contrast-enhanced component into the positron emission tomography-computerised tomography examination and the feasibility of dynamic contrast-enhanced computerised tomography at lung screening for the characterisation of solitary pulmonary nodules should be explored, together with a lower radiation dose protocol., Study Registration: This study is registered as PROSPERO CRD42018112215 and CRD42019124299, and the trial is registered as ISRCTN30784948 and ClinicalTrials.gov NCT02013063., Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 26, No. 17. See the NIHR Journals Library website for further project information.

Published
2022
Full Text
View/download PDF

50. Exploration of Relationships among Clinical Gastrointestinal Indicators and Social and Sensory Symptom Severity in Children with Autism Spectrum Disorder.

Author

Kreider CM, Mburu S, Dizdarevic S, Garvan G, and Elder JH

Abstract

Autism Spectrum Disorders (ASD) are associated with co-morbidities such as gastrointestinal (GI) symptomatology, which in the absence of known causes are potential indicators of gut microbiota that may influence behavior. This study's purpose was to explore relationships among clinical GI indicators-diet, abdominal pain, and stool status-and ASD symptom severity, specifically social and sensory symptoms. Participants were 33 children with ASD, 3 to 16 years. The Social Responsiveness Scale (SRS-2) and the Child Sensory Profile Scale (CSP-2) were used to appraise social and sensory symptomatology. Significant difference was found in overall SRS-2, t (31) = -3.220, p = 0.003 when compared by abdominal pain status using independent samples t -tests. Significant difference was observed for overall CSP-2, t (31) = -2.441, p = 0.021, when grouped by stool. The three clinical GI variables predicted overall SRS-2 score using multiple linear regression, F (3, 32) = 3.257, p = 0.036; coefficient for abdominal pain significantly contributed to the outcome. Findings contribute to the growing literature signaling the need to understand occurrence of GI symptomatology more deeply, and in consideration of diet status and its implications in the children's everyday lives, behaviors, and symptom severity.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results